Viking Therapeutic (VKTX) PT Raised to 'Street High' $28 at H.C. Wainwright

Viking Therapeutics (VKTX) Announces Proposed Common Share Offering

September 19, 2018 4:23 PM EDT

Viking Therapeutics, Inc. (NASDAQ: VKTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Viking also expects to grant to the underwriters of the offering a 30-day... More

Viking Therapeutic (VKTX) PT Raised to $28 at SunTrust Robinson Humphrey

September 18, 2018 3:39 PM EDT

SunTrust Robinson Humphrey analyst Edward Nash raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $28.00 (from $14.00) while maintaining a Buy rating.

Nash commented, "Viking announced promising results from a Phase II study of VK2809 in NAFLD/hypercholesterolemia. 12-week treatment... More

Viking Therapeutic (VKTX) PT Raised to $28 at Maxim Group, Matching 'Street High'

September 18, 2018 12:31 PM EDT

Maxim Group analyst Jason McCarthy raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $28.00 (from $14.00) while maintaining a Buy rating. The new price target matches a Street High.

The analyst highlights:

VKTX shares are up sharply (~+80%) after announcing positive top-line 12-week P2 data for VK2809, an oral thyroid beta receptor agonist (TR), in Non-Alcoholic Fatty... More

Pre-Open Movers 09/18: (VKTX) (NXEO) (TLRY) Higher; (MDGL) (ATHN) (CBRL) Lower (more...)

September 18, 2018 9:24 AM EDT

Today's Pre-Open Movers

Viking Therapeutics, Inc. (NASDAQ: VKTX) 120.7% HIGHER; announced positive top-line results from a 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C). The study successfully achieved its primary endpoint, with patients receiving VK2809 demonstrating statistically... More

Viking Therapeutics (VKTX): VK2809 Phase II Data Tops Madrigal's MGL-3196 - SunTrust

September 18, 2018 8:33 AM EDT

SunTrust Robinson Humphrey analyst, Edward Nash, reiterated his Buy rating on shares of Viking Therapeutic (NASDAQ: VKTX) after the company reported impressive data from the Phase II study of VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and elevated LDL-cholesterol. VK2809 reduced... More

Wall Street bounces back as investors shrug off trade tensions

September 18, 2018 7:41 AM EDT

By Stephen Culp

NEW YORK (Reuters) - Wall Street rebounded on Tuesday in a broad-based rally as investors brushed aside intensifying trade rhetoric between the United States and China.

All three major U.S. indexes closed higher following Monday's sell-off.

Late Monday, U.S. President Donald Trump announced that 10 percent tariffs on $200 billion in imports from China would go into effect next week, escalating the tit-for-tat trade spat between the world's two largest economies.

China responded on Tuesday by unveiling 10 percent tariffs on about $60 billion of U.S. goods effective Sept. 24.

"Initially they were... More

Viking Therapeutics (VKTX) Climbs 140% After Shares Resume Trading

September 18, 2018 7:37 AM EDT

Viking Therapeutics (NASDAQ: VKTX) Climbs 140% After Shares Resume Trading

... More

Viking Therapeutics (VKTX) to Resume Trading at 7:35 am ET

September 18, 2018 7:17 AM EDT

Viking Therapeutics (NASDAQ: VKTX) to Resume Trading at 7:35 am ET

... More

Viking Therapeutics (VKTX) Says Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol Achieved its Primary Endpoint

September 18, 2018 7:08 AM EDT

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from a 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease (NAFLD) and elevated... More